Karyopharm Therapeutics
(NASDAQ) KPTI
Karyopharm Therapeutics Financials at a Glance
Market Cap
$139.96M
Revenue (TTM)
$146.07M
Net Income (TTM)
$196.04M
EPS (TTM)
$-16.62
P/E Ratio
-0.46
Dividend
$0.00
Beta (Volatility)
1.29 (Average)
Dividend
$0.00
Beta (Volatility)
1.29 (Average)
Price
$7.56
Volume
1,496,158.535
Open
$7.76
Price
$7.56
Volume
1,496,158.535
Open
$7.76
Previous Close
$7.63
Daily Range
$7.43 - $9.04
52-Week Range
$3.51 - $10.99
Dividend
$0.00
Beta (Volatility)
1.29 (Average)
Price
$7.56
Volume
1,496,158.535
Open
$7.76
Previous Close
$7.63
Daily Range
$7.43 - $9.04
52-Week Range
$3.51 - $10.99
KPTI News
KPTI: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Karyopharm Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
228
CEO
Richard A. Paulson, MBA
Website
www.karyopharm.comHeadquarters
Newton, MA 02459, US
KPTI Financials
Key Financial Metrics (TTM)
Gross Margin
96%
Operating Margin
-62%
Net Income Margin
-1%
Return on Equity
0%
Return on Capital
-6%
Return on Assets
-2%
Earnings Yield
-2.17%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$139.96M
Shares Outstanding
18.34M
Volume
1.50M
Short Interest
0.00%
Avg. Volume
588.45K
Financials (TTM)
Gross Profit
$140.12M
Operating Income
$90.71M
EBITDA
$90.41M
Operating Cash Flow
$75.37M
Capital Expenditure
$0.00
Free Cash Flow
$75.37M
Cash & ST Invst.
$63.74M
Total Debt
$233.61M
Karyopharm Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$34.08M
+11.6%
Gross Profit
$32.59M
+11.6%
Gross Margin
95.65%
N/A
Market Cap
$139.96M
N/A
Market Cap/Employee
$501.67K
N/A
Employees
279
N/A
Net Income
$102.20M
-232.0%
EBITDA
$17.82M
+9.1%
Quarterly Fundamentals
Net Cash
$169.86M
-97.9%
Accounts Receivable
$26.18M
-14.9%
Inventory
$4.04M
-14.8%
Long Term Debt
$211.63M
+24.7%
Short Term Debt
$21.98M
-11.6%
Return on Assets
-1.81%
N/A
Return on Invested Capital
-5.55%
N/A
Free Cash Flow
$11.83M
+54.1%
Operating Cash Flow
$11.83M
+54.2%